Mirtazapine Reduced Methamphetamine Use in a Pragmatic Trial

A clinically relevant reduction in methamphetamine use

Mirtazapine reduced methamphetamine use among adults with methamphetamine use disorder in a randomized clinical trial designed to reflect routine practice. That combination—a positive efficacy result and a pragmatic setting—makes the finding especially relevant to addiction services, where patients commonly have co-occurring symptoms, inconsistent attendance and difficulty sustaining daily treatment.

Randomization strengthens the conclusion that mirtazapine caused the difference observed between groups within the study population. It does not establish that every patient will benefit, nor does it make the antidepressant an approved treatment for methamphetamine use disorder. In the United States, there remains no Food and Drug Administration-approved medication specifically for this condition.

The trial’s authors reported a reduction in methamphetamine use and described the treatment as safe in the study population. No unexpected safety concern was highlighted in the published report. The complete arm-level estimate, confidence interval, participant count and follow-up schedule should be read directly in the peer-reviewed article; those numerical details were not independently reproducible from the bibliographic material supplied for this brief and are therefore not restated here.

That distinction matters. A statistically significant average reduction can represent anything from a modest shift in days of use to a larger increase in abstinence, and those outcomes do not carry identical clinical meaning. Frequency, amount used, urine toxicology, craving, retention and functional recovery each capture different parts of treatment response.

Why the pragmatic design matters

Explanatory trials ask whether a treatment can work under tightly controlled conditions. Pragmatic trials are organized to ask whether it works when delivered more like ordinary care, often with broader eligibility, fewer study-only visits and treatment pathways that resemble existing services. For methamphetamine use disorder, that can make the result more useful to clinicians and policymakers deciding whether an inexpensive generic medicine merits implementation research.

Pragmatism also brings trade-offs. Variable adherence, missed assessments and use of other services can dilute an efficacy signal. Self-reported drug use may be affected by recall or reporting bias, while urine tests detect use only within a limited window. The strength of this trial therefore depends not only on randomization but also on retention, outcome completeness, adherence measurement and whether biological testing supported the reported behavioral outcome.

Mirtazapine is already familiar in psychiatric and primary care practice as an antidepressant. Its sedating and appetite-stimulating effects can be clinically relevant, particularly for people whose methamphetamine use is accompanied by insomnia, reduced appetite or depressive symptoms. Those properties are not evidence that it treats the substance use disorder, however. The randomized reduction in methamphetamine use is the key efficacy finding.

The new study also builds on earlier placebo-controlled research. A 2011 randomized trial involving 60 sexually active men who have sex with men found fewer methamphetamine-positive urine samples with mirtazapine than with placebo. A later trial of 120 cisgender men and transgender women who have sex with men reported a relative risk of methamphetamine-positive urine tests of 0.67 at 12 weeks, with a 95% confidence interval of 0.51 to 0.87. Both studies combined medication with counseling, and their narrowly defined populations limited broad generalization.

Where mirtazapine might fit in practice

The current evidence supports discussing mirtazapine as a possible off-label option, not presenting it as established pharmacotherapy. Behavioral treatment remains central. Contingency management has the strongest evidence among behavioral approaches for stimulant use disorders, although reimbursement, staffing and program rules continue to restrict access in many US settings.

An off-label decision would need to account for the patient’s treatment goals, co-occurring psychiatric conditions, other medicines and capacity for follow-up. Mirtazapine may be more practical than a tightly monitored or injectable regimen because it is generic and widely available, but availability alone does not establish comparative effectiveness or cost-effectiveness.

Safety also requires context. Sedation, increased appetite, weight gain and dizziness are recognized concerns with mirtazapine. These effects may impair adherence or create additional risk for some people, even when a trial detects no unexpected safety signal. Conversely, patients troubled by insomnia or poor appetite may view some effects differently.

Routine monitoring remains important because trial-level tolerability does not predict an individual response.

The finding should not be interpreted as evidence for using mirtazapine only when depression is present. Nor does it show that treating depression indirectly explains the reduction in methamphetamine use unless the trial’s prespecified analyses demonstrate mediation. Methamphetamine use disorder and depressive symptoms frequently coexist, but they remain distinct treatment targets.

Uncertainties that could shape adoption

Generalizability is the central question. Prior mirtazapine trials recruited specific sexual and gender minority populations, so a pragmatic study enrolling a broader clinical population would address an important evidence gap. Even then, applicability depends on the participants’ age range, severity of use, route of administration, housing stability, psychiatric comorbidity and use of fentanyl or other substances.

Duration matters as well. Methamphetamine use disorder is often chronic and relapsing. A reduction during active treatment may not persist after medication stops, and a short follow-up cannot establish long-term cardiovascular, psychiatric or functional benefit. Replication would also help determine whether the effect is robust across health systems and whether it extends to abstinence, retention, quality of life and reduced acute-care use.

Other limitations require attention in the full report: masking, missing outcome data, adherence, concomitant behavioral care, prespecified analysis methods, funding and investigator conflicts. A pragmatic label does not by itself guarantee representativeness. Clinicians and policymakers should examine who enrolled, who completed follow-up and how closely the comparison condition resembled treatment ordinarily available in their own settings.

For now, mirtazapine has a credible but still developing evidence base. The latest randomized result strengthens the case for larger effectiveness studies and for careful off-label consideration where clinicians can monitor benefit and adverse effects. It does not remove the need for behavioral treatment, harm-reduction services or management of co-occurring psychiatric and medical conditions.

Questions clinicians ask

Is mirtazapine approved for methamphetamine use disorder?

No. Mirtazapine is an antidepressant, and using it to treat methamphetamine use disorder is off-label in the United States. The pragmatic trial adds randomized evidence of reduced use, but regulatory approval would require a sufficiently complete efficacy and safety package reviewed for this specific indication.

Does the trial support prescribing mirtazapine without behavioral care?

Not on its own. Medication trials occur within a broader care environment, and earlier mirtazapine studies included counseling. The evidence supports viewing mirtazapine as a potential component of treatment rather than a replacement for contingency management, counseling, harm reduction, infectious-disease prevention or care for co-occurring illness.

Which adverse effects are most relevant?

Sedation, increased appetite, weight gain and dizziness are established concerns with mirtazapine. The pragmatic trial reportedly did not identify an unexpected safety signal, but its duration and sample size constrain detection of uncommon or longer-term harms. Individual risk assessment remains necessary, particularly when other sedating substances or medicines are involved.

How much confidence should clinicians place in this result?

Randomization supports a causal interpretation for the study population, and the routine-practice design improves clinical relevance. Confidence in broader use depends on the size and durability of the effect, missing data, adherence, participant diversity and replication. The trial strengthens the evidence base but does not by itself establish a universal standard of care.

References

1. Mirtazapine reduces methamphetamine use in adults with methamphetamine use disorder: randomized clinical trial — PubMed, 2026
2. Mirtazapine to reduce methamphetamine use: a randomized controlled trial — PubMed, 2011
3. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial — PubMed, 2020
4. Methamphetamine — National Institute on Drug Abuse, n.d.